Recordati

Pharma

CVC Capital offers $12.6B to buy out Italian pharma Recordati

CVC has offered to buy out Recordati for 10.9 billion euros ($12.6 billion). The investment firm intends to delist the company.

Kevin Dunleavy Mar 27, 2026 7:37am

Amarin Vascepa box

Amarin sells Vascepa's rights in Europe to Recordati for $25M

Jun 24, 2025 11:26am

pay deal hand over cash licensing transaction money

Sanofi sells rare disease med Enjaymo to Recordati for $825M

Oct 4, 2024 10:11am

signing contract

Recordati to acquire EUSA Pharma for €750m ($845 million)

Dec 3, 2021 11:10am

approved

Recordati scores FDA nod for Cushing's disease med Isturisa

Mar 9, 2020 11:58am

Novartis headquarters

Novartis offloads endocrine drugs to Recordati for $390M

Jul 15, 2019 12:25pm